Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]
News [7018]
Articles [265]
Editorials [8]
Conferences [213]
elearning [41]
Significant survival gains for neoadjuvant chemotherapy for high risk soft...
Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
How can we improve the reliability and quality of cancer registries?
Dr Ana-Maria Forsea - Carol Davila University of Medicine and Pharmacy...
How can we improve the reliability and quality of cancer registries? ( Dr Ana-Maria Forsea - Carol Davila University of Medicine and Pharmacy Bucharest, Bucharest, Romania )
10 Oct 2016
Negative trial results of custirsen for metastatic prostate cancer
Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif...
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Cabozantinib improves PFS in metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib improves PFS in metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
Advances for NSCLC in review
Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab new option for firstline treatment of advanced lung cancer with...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Pembrolizumab plus chemo as firstline therapy for NSCLC
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation